ClinicalTrials.gg
RecruitingNCT04739319Project AMDUpdated Feb 9, 2024

Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression

An observational study in Age Related Macular Degeneration, Geographic Atrophy and AMD, sponsored by Center for Eye Research Australia. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-09.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Center for Eye Research Australia · Observational

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Geographic Atrophy with a site in Australia — 12 open to participants now, 15 under way, 4 of them phase 3. Geographic Atrophy · Australia.

Started
2021
with 4 others
Observational
7 of 41
2 open now
Primary completion
2040-11
later than 14 of 14 live
Registered
23rd of 41
by date

Among the 41 studies in Geographic Atrophy with a site in Australia, this one is one of 5 that started in 2021, is one of 7 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 23rd registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

12 of the 41 studies in Geographic Atrophy with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Geographic Atrophy with a site in Australia, or all of them as a file.
02

Study summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD. This proposed project is a prospective, observational study that seeks to to understand the underlying aetiology of AMD, factors associated with differences between age-related macular degeneration (AMD) phenotypes or severities, or between AMD and healthy individuals. It also seeks to understand the natural history of AMD progression and the factors associated with the rate of progression. In this project, the disease phenotype, genotype and severity and rate of progression will be determined based on non-invasive clinical imaging or functional assessment of the retina, from obtaining biological samples from the participants, or from patient-reported outcomes.

03

Conditions studied

  • Age Related Macular Degeneration
  • Geographic Atrophy
  • AMD
  • Age-related Macular Degeneration

Browse trials for

Keywords

  • Age Related Macular Degeneration
  • Geographic Atrophy
  • Drusen
  • Macular disease
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 130 across 39 observational studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Center for Eye Research Australia is the lead sponsor of 12 studies on the registry; 6 are open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

People in Australia aged 18 years or older with AMD or healthy controls, willing and able to provide informed consent, and willing to accept the study requirements.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older; and
  2. either AMD (defined as having at least a medium druse >63 um), or having eyes with normal ageing changes (including small drusen ≤63 um) or no abnormalities as control participants

Exclusion criteria

Exclusion Criteria:

  1. ocular or systemic conditions other than AMD that could compromise retinal assessment or assessment of AMD and its progression; or
  2. any participant with any mental or physical impairment that prevents them from signing an form or participating in this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Age-Related Macular Degeneration

    Participants with Age-Related Macular Degeneration

    Other: N/A Observational study

Interventions

  • OtherN/A Observational study

    N/A Observational study

07

What researchers measure

Primary outcomes

  1. Investigate the underlying aetiology of Age-Related Macular Degeneration

    The first aim of this project is to comprehensively investigate the underlying aetiology of AMD, characterise the AMD phenotype by understanding the differences between those with AMD and healthy individuals.

    Time frame: Up to 20 years

  2. Characterise the natural history of Age-Related Macular Degeneration and factors associated with its rate of progression.

    The second aim of this project is to characterise the natural history of AMD and factors associated with its rate of progression. These aims will be achieved by using performing imaging and functional assessment of the retina, characterisation of the genetic, systemic and environmental factors, and by obtaining patient-reported outcomes.

    Time frame: Up to 20 years

08

Study locations

1 of 1 sites recruiting
09

References and documents

Related links

Individual participant data

Plan to share: Yes — All collected IPD at the discretion of the Principal Investigator in a de-identified format

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2021 (actual). Primary completion is estimated for Nov 2040, 237 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Feb 4, 2021
StartActual
Feb 2, 2021
Primary completionEst.
Nov 2040
CompletionEst.
Nov 2040
Last update
Feb 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04739319
Lead sponsor
Center for Eye Research Australia
Responsible party
Sponsor
First posted
Feb 4, 2021
Start date
Feb 2, 2021
Primary completion
Nov 2040 (estimated)
Completion
Nov 2040 (estimated)
Last update
Feb 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion